The combined protease inhibitor lopinavir/ritonavir, primarily used for HIV infection, has demonstrated an in vitro activity against SARS-CoV via the inhibition of 3-chymotrypsin-like protease [39,40]. The gene discussed is CTRL; the disease is HIV infectious disease.